Cargando…
D‐1553: A novel KRAS(G12C) inhibitor with potent and selective cellular and in vivo antitumor activity
D‐1553 is a small molecule inhibitor selectively targeting KRAS(G12C) and currently in phase II clinical trials. Here, we report the preclinical data demonstrating antitumor activity of D‐1553. Potency and specificity of D‐1553 in inhibiting GDP‐bound KRAS(G12C) mutation were determined by thermal s...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323112/ https://www.ncbi.nlm.nih.gov/pubmed/37158138 http://dx.doi.org/10.1111/cas.15829 |